Just call me Nostradamus, because Lupin Ltd. is the next generics manufacturer to fall foul of the FDA. The company's US arm, Lupin Pharmaceuticals Inc, voluntarily withdrew nearly 10,000 bottles of the branded antibiotic Suprax (cefixime). Much like in Sun's case, the company claims that this is a "voluntary recall" which is of "no business consequence". Lupin also withdrew over 64,000 bottles of the drug last year, due to problems with discoloration.
Again, taken in isolation, the incident may indeed not be of much business consequence. But as pointed out on Fierce Pharma,
"The laundry list of product bans, FDA warning letters and recalls at Ranbaxy and its Indian rivals have prompted new scrutiny not only by regulatory agencies around the world, but by pharmacology experts who worry that Indian-made generics aren't as effective as their brand-name counterparts."